Member Info for Jezzab1970

Getting quoted 15.58 for £100k in shares on IG!

Discussions with global sportswear leader and tier 1 automotive manufacturer. Fullyvfunded and Market cap only £2m - let that sink in......

Continues.... Lab-Grown Leather (LGL): Capitalising on our newly achieved A4-sized tannable skin milestones and active B2B corporate assessment pipelines.

● 3D Bio-Tissues (3DBT): Scaling commercial supply agreements for our cellular nutrition enhancers (City-Mix™ and CytoBoost™ Revive) with international partners like SeaWith, driving near-term commercial revenue.

● Kerato Limited: Progressing toward veterinary and clinical safety targets for our tissue-engineered corneal repair solutions, capturing a vital footprint in the advanced MedTech space.

The Board is confident that our multi-pillar structure limits risk while multiplying value-inflection milestones, ensuring parent PLC shareholders remain exposed to an expansive industrial IP engine rather than a single consumer luxury asset.

Dr. Che Connon, CEO of BSF Enterprise, commented:

"The Paris auction was a public display of an incredible engineering feat: turning abstract, ancient genetic information into a dense, beautifully structured, physical material via our scaffold-free platform. While the public auction bidding didn't meet our historic reserve, the commercial validation we required has been emphatically achieved. The multi-billion-dollar automotive and footwear giants currently considering our materials aren't interested in buying a handbag at auction; they are interested in licensing the platform architecture that created it. BSF is treating biology as software, and our industrial trajectory remains firmly on track."

Key Highlights:

● Proof of Structural Capability: The fabrication and craftsmanship of the Enfin Levé T-Rex Leather™ handbag successfully validated the structural integrity and physical performance of the Company's proprietary Advanced Tissue Engineering Platform (ATEP™).

● Transition to Private Sale: Public bidding reached €150,000, falling short of the historical reserve price. The piece has been withdrawn from public auction and is transitioning to a private sale process targeting parties that expressed interest at the auction, institutional collectors, museums, and high-net-worth individuals.

● Acceleration of Tier-1 Commercial Dialogues: The high global visibility of the Paris exhibition has generated an acceleration of inbound interest from multi-billion-dollar enterprise partners, specifically across global automotive interiors and premium performance sportswear brands evaluating material integration.

● Diversified Revenue Streams Unaffected: The core value of BSF remains heavily insulated by parallel commercial trajectories across cell culture media additives (City-Mix™ and CytoBoost™ sales pipelines) and imminent advanced medtech clinical corneal repair milestones (Kerato Ltd).

A System Validation, Not an End-Consumer Asset

The Board notes that recent market sentiment surrounding the public auction has conflated a specialised, museum-grade technical demonstration with the Company's broader commercial output. The primary objective of the T-Rex Leather™ project was never to establish BSF as a consumer fashion retailer, but rather to subject our scaffold-free, computational biology platform to the most extreme manufacturing stress-test possible.

To successfully construct a high-performance luxury asset requiring deep structural density, complex stitching, and industrial tanning from synthesized, extinct DNA sequences represents total proof-of-concept validation for our engineering biology systems.

Commercial Inbound & Platform Scale

While public auction bidding closed at €150,000, the visibility generated has significantly de-risked our material science vertical. BSF is currently advancing technical evaluations with major international corporations, including:

1. A Global Sportswear Leader: Steps towards evaluating the performance and branding characteristics of our ATEP™ sheets for next-generation performance footwear applications.

2. A Tier-1 Automotive Manufacturer: Discussing technical feasibility studies on the scalability of our bio-synthetic hide for bespoke, sustainable vehicle upholstery.

Crucially, our underlying business model for LGL relies on eventual high-volume industrial supply, licensing agreements, and the sale of automated bioreactor infrastructure to these mass-market verticals, rather than the sale of one artisan luxury accessory.

Strong Balance Sheet and Multi-Asset Insulation

Supported by our recently announced £1 Million interest-free Convertible Loan Note with Indigo

Brilliant RNS - says it all

Strategic Progress

The Board believes 2026 represents a critical time for BSF and its shareholders based on three key pillars:

1. Progressing from R&D towards Commercialisation: The Company has made significant progress in translating its research programmes into commercial and clinical-stage activities. The T-Rex leather exists, Kerato trials are live, and CytoBoost™ is shipping.

2. Simultaneous Infrastructure Upside: Unlike single-asset plays, there are three completely distinct high-growth assets simultaneously , distributing risk and multiplying potential upside events.

3. Anti-Dilutive Spin-Out Structure: The Board is evaluating potential subsidiary-level financing options, including possible spin-out structures, which may enable future growth capital to be raised at subsidiary level.

Management Leadership

The execution of these commercial milestones is led by a highly experienced technical and capital markets management team:

● Dr. Che Connon (Managing Director): International leader in Tissue Engineering with over 100 publications; founder of four previous biotech spin-outs.

● Geoff Baker (Executive Director): Qualified lawyer (Australia & Hong Kong) with an extensive track record commercialising biomedical and industrial innovations.

● Graham Duncan (CFO): Chartered Accountant with more than 20 years of capital markets experience, holding an ICAEW Corporate Finance Diploma.

● Ricardo Gouveia (CSO): Bioengineering and biochemistry specialist with 20 years of dedicated research in stem cell and tissue biofabrication.

BSF Enterprise PLC ("BSF" or the "Company"), a biotech platform company driving a bio-sustainable future through its three high-growth subsidiaries, announces updates to its strategic operations for 1/2-year 2026. The activities are structured to accelerate commercialisation with imminent value-inflection milestones across BSF's three subsidiaries -beyond any existing research and development (R&D).

Key Milestones & Near-Term Catalysts

Lab-Grown Leather Ltd (LGL) - Lead Catalyst (June 2026)

● World-First Product Launch: LGL has developed T-Rex Leather™- high-end leather alternative grown from synthetic dinosaur DNA using BSF's proprietary ATEP™ scaffold-free tissue manufacturing platform.

● Paris Auction: A tanned T-Rex skin has been completed, and a world-first luxury avant-garde handbag has been manufactured by a Berlin-based designer. The item is scheduled to be auctioned on June 11 at Dourot, a leading Paris auction house, supported by a global PR campaign and marketing by VML.

● Spin-Out Pathway: Post-catalyst, LGL will seek independent spin-out funding to scale production capacity, allowing it to raise capital at the subsidiary level without diluting BSF parent shareholders.

Kerato Ltd - Clinical Results & Commercialisation (Q3-Q4 2026)

● LiQD Cornea™ Hydrogel: Targeting the expanding corneal transplant world market.

● Veterinary Clinical Trials: Phase 1 veterinary trials (50% funded by Canadian government grants) commenced in Q1 2026. Kerato has reached the midpoint of its PSO-funded development programme for LiQD Cornea, achieving key technical, regulatory and operational milestones. These include a successful pre-ITA engagement meeting with Health Canada and ongoing implementation of an ISO 13485-compliant quality management system to support future clinical translation activities.

● Commercial Outlook: Kerato aims to sign commercial distribution agreements in Q4 2026 , leading to first commercial veterinary sales in early 2027. Applications for human trials with Health Canada are planned for 2026-2027. Similar to LGL, a subsidiary-level self-funding spin-out is planned post-catalyst.

3D Bio-Tissues Ltd (3DBT) - Commercial Momentum (Active Now)

● Revenue Generation: Targeting the massive bio-based materials world market. 3DBT has commercially launched its CytoBoost™ REVIVE media factor into biopharma and expanded sales of its City-MixR product into cultivated meat sectors.

● Sales Growth: 3DBT has experienced significant growth in customer orders over a recent 3-month period.

● Commercial Pipeline: Secured a supply agreement with Seawith, yielding an active £500,000 pipeline. New cultivated meat partnerships and further biopharma client expansions are progressing through Q2 and Q3 2026.

Recent raise ( 2 weeks ) at 2p and warrants at 3.57. Cash available currently around mcap. Discussions with Tier 1 brands.

Looks cheap to me

Not to mention the cultivated meat business and the corneal work in Canada.

Guys. You need to forget about the bag. It was never about the bag other than using it as a worldwide advertising campaign which has been done pretty effectively. Its about the IP and the fact they can replicate any animal skin which means rare,endangered and extinct animals can now adourn luxury cars, accessories,shoes and anything else you can think of. Fully funded and teir 1 clients at the door for around a meagre £3m mcap. Just let that sink in. DYOR

You pay your money and you make your choice. My money is on this doing well - lets see

Alot of value to be realised due to the tech capabilities and interest from Tier 1 companies.

Total overeaction! It was a combination of people being disappointed with the auction yesterday (no idea why as it is pretty meaningless in the scheme of things) and MM's taking advantage of friday trading. Will be back up again next week given the recent raise on the 3rd June at 2p and the warrants from yesterday a 3.57p

That's it I'm not buying anymore!! Buy and hold is my plan - given the tech and the size of the market place, hopefully within 6 months I'll have enough to retire on!!!

Must be short of shares as I can sell loads but buy very little. Had to put orders in earlier to buy any at all - bodes well for next week

£5M buy just showing - someone certainly sees value

Funding seems to be out of the way so you would assume this is the bottom and will only rise from here . DYOR

I have taken the opportunity to average down. Everyone seems to be forgetting the raise at 2p on 3rd June and the fact that warrants have been issued at 3.57p yesterday!! All it takes is an RNS regards a tie up with at least one of the tier one's they have mentioned and this will be back over 2p in an instant. DYOR

Someone is continuing to accumulate here - I wonder who and what they know?

The court adjourned the hearing to allow additional time to review the case